Thank you for participating!

Thank you to all who contributed to the National Heart, Lung, and Blood Institute (NHLBI) Strategic Visioning Forum. Ultimately, over 1,000 ideas were submitted, with more than 42,000 votes. This remarkable response exceeded expectations and provided a wealth of ideas to draw upon as NHLBI moves forward. Please visit the NHLBI Strategic Visioning page to find out more about the NHLBI Strategic Visioning process.


Welcome to the National Heart, Lung, and Blood Institute (NHLBI) Strategic Visioning Forum. The Institute is gathering ideas for the most compelling scientific priorities in the four NHLBI Strategic Goals to address over the next decade.

Goal 2: Reduce Human Disease

Submitted by (@moshe.arditi)

More funding for Kawasaki Disease Vasculitis

Kawasaki Disease is the most common cause of acquired heart disease among children and we just started to understand that Kawasaki Disease 9 unrecognized during childhood) maybe responsible for a large number of adult atherosclerotic diseases and excellent animal models for this vasculitis exist and more funding should be allocated for this disease. We are now starting to understand that Kawasaki Disease is NOT a self ...more »

Voting

2 net votes
2 up votes
0 down votes
Active

Goal 2: Reduce Human Disease

Submitted by (@anna.adachimejia)

Design interventions to improve sleep hygiene

Inadequate sleep is associated with risk of obesity. Electronic media devices interfere with our ability to sleep well - they delay sleep, interrupt sleep, and affect sleep quality. However these devices are addictive and ubiquitous. Can we develop interventions to help people obtain adequate sleep?

Voting

2 net votes
2 up votes
0 down votes
Active

Goal 3: Advance Translational Research

Submitted by (@nhlbiforumadministrator)

Maximizing Previous Investment in Existing Cohorts

Everyone would like to see integration of genomic, metabolomic, epigenomic, proteomic, transcriptomic, etc. data analyzed in the context of clinical disease, environmental influences, and even end-organ effects (lung versus heart or blood as an example). Rarely can this occur on small cohorts, but rarely are funds available to take maximum use of existing large cohorts and the samples and information collected within ...more »

Voting

22 net votes
34 up votes
12 down votes
Active

Goal 3: Advance Translational Research

Submitted by (@soldatovn.humgenex)

Calcium channels in cardiovascular functions and diseases

Fifty years ago Prof. Harald Reuter of the University of Bern, Switzerland obtained the first experimentally supported evidence that the calcium channel is a physiologically distinct entity. Further stimulated by the synthesis of the dihydropyridine calcium channel blocker nifedipine, the field of calcium channel research rapidly encompassed cardiovascular and other powerful biomedical directions.

Voting

-2 net votes
1 up votes
3 down votes
Active

Goal 3: Advance Translational Research

Submitted by (@chintamani.atreya)

Tools to facilitate availability and safe use of innovative blood products and their analogs

Novel blood products are being developed based on innovative science (e.g., ex vivo manufactured RBC and platelets, and platelet and plasma derived hemostatic products). However, there is a significant lag in the development of appropriate tools and model systems, which poses a challenge when evaluating such products for regulatory approval.

Voting

12 net votes
17 up votes
5 down votes
Active